Total Payments
$104,773
2024 Payments
$58.62
Companies
24
Transactions
206
Medicare Patients
3,645
Medicare Billing
$544,849
Payment Breakdown by Category
Research$101,965 (97.3%)
Food & Beverage$2,808 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $101,965 | 15 | 97.3% |
| Food and Beverage | $2,808 | 191 | 2.7% |
Payments by Type
Research
$101,965
15 transactions
General
$2,808
191 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lupin Inc. | $84,784 | 9 | $0 (2018) |
| First Wave BioPharma, Inc. | $9,552 | 5 | $0 (2022) |
| Eli Lilly and Company | $7,630 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $461.63 | 29 | $0 (2023) |
| GlaxoSmithKline, LLC. | $430.29 | 38 | $0 (2023) |
| Grifols USA, LLC | $377.04 | 26 | $0 (2023) |
| Philips Electronics North America Corporation | $374.33 | 18 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $272.70 | 18 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $182.56 | 13 | $0 (2019) |
| Genentech USA, Inc. | $136.52 | 16 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $58.62 | 3 | Axsome Therapeutics, Inc. ($34.38) |
| 2023 | $204.95 | 10 | Axsome Therapeutics, Inc. ($73.13) |
| 2022 | $9,605 | 7 | First Wave BioPharma, Inc. ($9,552) |
| 2021 | $7,780 | 10 | Eli Lilly and Company ($7,630) |
| 2020 | $134.74 | 9 | Harmony Biosciences LLC ($52.09) |
| 2019 | $770.36 | 49 | Philips Electronics North America Corporation ($174.08) |
| 2018 | $85,348 | 46 | Lupin Inc. ($84,784) |
| 2017 | $870.35 | 72 | Grifols USA, LLC ($227.75) |
All Payment Transactions
206 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Neurology | ||||||
| 07/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: RESPIRATORY | ||||||
| 02/05/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Neurology | ||||||
| 12/18/2023 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Neurology | ||||||
| 11/27/2023 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Neurology | ||||||
| 11/16/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.24 | General |
| 08/15/2023 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Neurology | ||||||
| 08/02/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: RESPIRATORY | ||||||
| 05/03/2023 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: Pulmonology | ||||||
| 04/25/2023 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: Neurology | ||||||
| 04/18/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Respiratory | ||||||
| 03/16/2023 | Harmony Biosciences LLC | WAKIX (Drug) | Food and Beverage | Cash or cash equivalent | $29.76 | General |
| Category: SLEEP MEDICINE | ||||||
| 01/31/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2022 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Respiratory | ||||||
| 09/28/2022 | First Wave BioPharma, Inc. | — | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: Niclosamide | ||||||
| 09/28/2022 | First Wave BioPharma, Inc. | — | — | Cash or cash equivalent | $2,350.00 | Research |
| Study: Niclosamide | ||||||
| 09/28/2022 | First Wave BioPharma, Inc. | — | — | Cash or cash equivalent | $1,352.00 | Research |
| Study: Niclosamide | ||||||
| 09/28/2022 | First Wave BioPharma, Inc. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: Niclosamide | ||||||
| 09/28/2022 | First Wave BioPharma, Inc. | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: Niclosamide | ||||||
| 04/27/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.21 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/04/2021 | Horizon Therapeutics plc | RAYOS (Drug), RAYOS, RAYOS | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: RAYOS | ||||||
| 10/13/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $11.93 | General |
| 09/28/2021 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Respiratory | ||||||
| 09/14/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: RESPIRATORY | ||||||
| 08/10/2021 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $84,784 | 9 |
| Niclosamide | First Wave BioPharma, Inc. | $9,552 | 5 |
| ADAPTIVE PLATFORM TREATMENT TRIAL FOR OUTPATIENTS WITH COVID-19 | Eli Lilly and Company | $7,630 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,012 | 1,345 | $365,833 | $108,850 |
| 2022 | 12 | 915 | 1,293 | $422,343 | $123,194 |
| 2021 | 13 | 854 | 1,260 | $452,452 | $131,170 |
| 2020 | 14 | 864 | 1,420 | $521,074 | $181,635 |
Total Patients
3,645
Total Services
5,318
Medicare Billing
$544,849
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 184 | 358 | $223,711 | $56,304 | 25.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 161 | 285 | $54,759 | $25,117 | 45.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 56 | 60 | $6,900 | $4,964 | 71.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 113 | 115 | $14,375 | $3,991 | 27.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 110 | 111 | $16,095 | $3,849 | 23.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 144 | 157 | $13,502 | $3,330 | 24.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 130 | 140 | $15,680 | $3,283 | 20.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $4,458 | $2,627 | 58.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 19 | $5,659 | $2,495 | 44.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 22 | 23 | $3,380 | $1,363 | 40.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 17 | $2,006 | $898.35 | 44.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 18 | 21 | $4,788 | $470.82 | 9.8% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 13 | 13 | $520.00 | $156.36 | 30.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 206 | 491 | $307,884 | $82,643 | 26.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 144 | 224 | $38,528 | $17,547 | 45.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 105 | 105 | $13,500 | $4,239 | 31.4% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 105 | 106 | $15,515 | $4,101 | 26.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 112 | 115 | $12,880 | $2,999 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 32 | $3,677 | $2,839 | 77.2% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 119 | 125 | $10,750 | $2,767 | 25.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $2,839 | $1,904 | 67.1% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2022 | 15 | 15 | $6,150 | $1,580 | 25.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 21 | 21 | $3,024 | $1,114 | 36.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 18 | $2,124 | $883.28 | 41.6% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 24 | 24 | $5,472 | $579.56 | 10.6% |
About Jan Westerman
Jan Westerman is a Critical Care Medicine healthcare provider based in Jasper, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285674150.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jan Westerman has received a total of $104,773 in payments from pharmaceutical and medical device companies, with $58.62 received in 2024. These payments were reported across 206 transactions from 24 companies. The most common payment nature is "" ($101,965).
As a Medicare-enrolled provider, Westerman has provided services to 3,645 Medicare beneficiaries, totaling 5,318 services with total Medicare billing of $544,849. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Jasper, AL
- Active Since 06/07/2006
- Last Updated 02/24/2022
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1285674150
Products in Payments
- TIOTROPIUM (Drug) $84,784
- BEVESPI AEROSPHERE (Drug) $293.24
- Prolastin-C (Biological) $286.98
- OFEV (Drug) $259.51
- TRELEGY ELLIPTA (Drug) $157.04
- inCourage (Device) $148.24
- UTIBRON (Drug) $135.93
- ANORO (Drug) $128.59
- BREO (Drug) $115.55
- Sunosi (Drug) $107.51
- Esbriet (Biological) $107.08
- Prolastin-C Liquid (Biological) $90.06
- FASENRA (Biological) $79.58
- Wakix (Drug) $75.43
- Respiratoriy Care Undiv (Device) $73.27
- Wellcentive Undiv (Device) $59.67
- DUPIXENT (Biological) $52.43
- TUDORZA PRESSAIR (Drug) $38.37
- (8874) inCourage (Device) $38.12
- Arikayce (Drug) $38.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.